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When it just won’t go away: oral 
artemisinin monotherapy in Nigeria, 
threatening lives, threatening progress
ACTwatch Group1*, Chinazo Ujuju2, Jennifer Anyanti2, Paul N. Newton3,4 and Godwin Ntadom5
Abstract 
Background: Oral artemisinin monotherapy (AMT), an important contributor to multi-drug resistant malaria, has 
been banned in Nigeria. While oral AMT has scarcely been found for several years now in other malaria-endemic 
countries, availability has persisted in Nigeria’s private sector. In 2015, the ACTwatch project conducted a nationally 
representative outlet survey. Results from the outlet survey show the extent to which oral AMT prevails in Nigeria’s 
anti-malarial market, and provide key product information to guide strategies for removal.
Results: Between August 10th and October 3rd, 2015 a total of 13,480 outlets were screened for availability of anti-
malarials and/or malaria blood testing services. Among the 3624 anti-malarial outlets, 33,539 anti-malarial products 
were audited, of which 1740 were oral AMT products, primarily artesunate (n = 1731). Oral AMT was imported from 
three different countries (Vietnam, China and India), representing six different manufacturers and 11 different brands. 
Availability of oral AMT was highest among pharmacies (84.0%) and Patent Propriety Medicine Vendors (drug stores, 
PPMVs) (38.7%), and rarely found in the public sector (2.0%). Oral AMT consisted of 2.5% of the national anti-malarial 
market share. Of all oral AMT sold or distributed, 52.3% of the market share comprised of a Vietnamese product, 
 Artesunat®, manufactured by Mekophar Chemical Pharmaceutical Joint Stock Company. A further 35.1% of the 
market share were products from China, produced by three different manufacturers and 12.5% were from India by 
one manufacturer, Medrel Pharmaceuticals. Most of the oral AMT was distributed by PPMVs accounting for 82.2% of 
the oral AMT market share. The median price for a package of artesunate ($1.78) was slightly more expensive than 
the price of quality-assured (QA) artemether lumefantrine (AL) for an adult ($1.52). The median price for a package of 
artesunate suspension ($2.54) was three times more expensive than the price of a package of QA AL for a child ($0.76).
Conclusion: Oral AMT is commonly available in Nigeria’s private sector. Cessation of oral AMT registration and 
enforcement of the oral AMT ban for removal from the private sector are needed in Nigeria. Strategies to effectively 
halt production and export are needed in Vietnam, China and India.
Keywords: Oral artemisinin monotherapy, Market share, Manufacturing, Anti-malarial products, Availability, Drug-
resistance
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Background
In 2007, the World Health Organization (WHO) rec-
ommended that oral artemisinin monotherapy (AMT) 
should no longer be manufactured, produced, or dis-
tributed, given that its use leads to multi-drug resistant 
malaria [1]. Oral AMT was banned because of its role 
in development of malaria parasite resistance to arte-
misinin and its derivatives [2]. Artemisinin-resistant 
parasites are particularly problematic because the only 
effective therapy for Plasmodium falciparum malaria is 
artemisinin-based combination therapy (ACT); no alter-
native medicines are currently available. The loss of ACT 
efficacy would be disastrous for malaria endemic coun-
tries and would severely impede global malaria control 
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and elimination progress [1]. Results from ACTwatch 
outlet surveys have shown that within a few years of the 
WHO recommendation, oral AMT was no longer avail-
able to consumers in multiple malaria endemic countries 
[3, 4]. The exception is ongoing availability and distribu-
tion in Nigeria, as described further in this paper, as well 
as in Myanmar, where oral AMT continues to be avail-
able and distributed despite the country’s national policy 
which has banned the use and importation of this anti-
malarial [5–7].
In line with recommendations by WHO to remove 
oral AMT from the market, Nigeria banned oral AMT in 
2006 [8]. Despite the ban, available evidence suggests that 
the National Agency for Food and Drug Administration 
and Control (NAFDAC) continues to issue product regis-
tration for oral AMT products as evidenced by NAFDAC 
registration numbers on product packaging. Further-
more, oral AMT products are marked by recent con-
sumer protections to safeguard against fake anti-malarial 
medicines. Mobile authentication services for registered 
anti-malarial products have been extended to oral AMT 
products. For example, artesunate tablets manufactured 
by Mekophar Chemical Pharmaceutical Joint Stock Com-
pany in Vietnam were found carrying a Sproxil code for 
verification by SMS messaging (Additional file 1).
Results from previous national ACTwatch outlet sur-
veys show that while oral AMT availability has declined 
in Nigeria’s private sector from 2009, when nearly half of 
private sector outlets were stocking oral AMT, in 2013 
oral AMT was still found on the market with one in four 
private sector outlets stocking this anti-malarial [9]. 
This decline may in part be attributed to the aforemen-
tioned national ban on oral AMT, but also private sector 
initiatives designed to increase access to first-line ACT 
through a private sector co-payment mechanism.
The continued presence of oral AMT on the market 
in Nigeria threatens malaria control progress in a coun-
try with one of the highest contributions to the global 
malaria burden [5]. Furthermore, use of oral AMT in 
Nigeria could fuel parasite resistance to artemisinins as 
has occurred elsewhere in the world [10, 11]. Information 
about any continued availability of oral AMT in Nigeria, 
including product information to guide strategy, is there-
fore urgently needed.
ACTwatch was launched in 2008 by Population Ser-
vices International (PSI) in collaboration with the Lon-
don School of Hygiene and Tropical Medicine with 
support from the Bill and Melinda Gates Foundation 
(BMGF), the Department for International Develop-
ment (DFID) and UNITAID. The goal of the project was 
to generate timely, relevant and high quality evidence 
on anti-malarial markets for policy makers, donors and 
implementing organisations [12]. As of 2016, ACTwatch 
had gathered data from a total of 12 malaria endemic 
countries in sub-Saharan Africa and the Greater Mekong 
Sub-region [3, 13]. Outlet surveys were designed to mon-
itor availability, price and market share in the context of 
national strategies to improve access to national first-line 
ACT medicines, including but not limited to the private 
sector co-payment mechanism.
This article provides timely, relevant information 
regarding the availability and distribution of oral AMT in 
Nigeria in 2015, including relevant and specific product 
information. This information will be critical for national 
and international strategies to halt the continued manu-
facturing, export/import, and distribution of oral AMT 
in Nigeria.
Methods
Sampling
A nationally representative antimalarial outlet survey was 
conducted in Nigeria between August 10th and October 
3rd, 2015. All categories of outlets with the potential to 
stock anti-malarials in both the public and private sec-
tor were included in the study. In the public sector, this 
included public health facilities (federal or state public 
facilities including teaching hospitals and federal medi-
cal centres at the tertiary level, general hospitals at the 
secondary level, and primary health centres and clinics 
at the primary level), community health workers (CHW) 
(including community health extension workers and role 
model mothers) and non-government, not-for-profit 
health facilities (hospitals and clinics). Outlets sampled in 
the private sector included private for-profit health facili-
ties (hospitals, centres and clinics), pharmacies (licensed 
by the Pharmacy Council of Nigeria), drug stores [known 
as patent proprietary medicine Vendors (PPMVs)], gen-
eral retailers selling fast-moving consumer goods, and 
itinerant drug vendors (mobile vendors without a fixed 
service delivery point).
As lists of all potentially eligible outlets were not rou-
tinely available, a cluster sampling approach with an 
outlet census in sampled clusters was used to identify 
outlets for inclusion [14, 15]. This entails sampling a set 
of administrative units with a population of approxi-
mately 10,000–15,000 inhabitants. In Nigeria, the most 
appropriate administrative unit matching this desired 
population size was a locality. A representative sample of 
localities was selected from with probability proportional 
to size within each of the six research domains: South–
West, South–South, South–East, North–West, North–
East, and North–Central. A stratified sampling approach 
was taken to produce estimates for each of these six geo-
political zones. The sampling frame excluded areas with 
security issues that could threaten the safety of data col-
lection teams.
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The study was powered to detect change over time in 
the availability of quality-assured (QA) ACT (QAACT) 
and malaria blood testing. QAACT was defined as ACTs 
that achieved accredited status from the WHO, European 
Medicines Authority (EMA) or the Global Fund [16]. A 
series of calculations identified minimum sample size 
requirements to detect an increase or decrease in two 
key indicators: (1) proportion of outlets with QAACT 
available, among outlets with antimalarial(s) in stock on 
the day of the survey; and (2) proportion of outlets with 
malaria blood testing (RDT or microscopy) available, 
among outlets with antimalarial(s) in stock on the day 
of the survey or within the past 3  months. Calculations 
examined the sample size required to detect a 20-per-
centage point change between 2013 and 2015 among all 
outlets, public health facilities, and PPMVs.
The average numbers of outlets by facility type in local-
ities within each geo-political zone screened during the 
2013 outlet survey were used to estimate the number of 
clusters required in 2015 to achieve the desired sample 
sizes. Considering sample size requirements to detect 
change over time and average numbers of outlets across 
each outlet type, the optimal minimum number of locali-
ties required to reach desired numbers of outlets was 296 
localities: n  =  45 North–Central, n  =  36 North–East, 
n = 59 North–West, n = 25 South–East, n = 31 South–
South, n = 100 South–West.
Within selected clusters, a census of all outlets with 
the potential to sell or distribute anti-malarials and/or 
provide malaria blood testing was completed. To imple-
ment the census, interviewers systematically searched for 
all the aforementioned outlet types. Maps were used to 
identify the cluster boundaries and key informants were 
also used to ensure an exhaustive search was completed 
in each area. As outlets were identified, interviewers 
approached providers and were administered a series of 
screening questions to determine eligibility. Outlets eli-
gible for the survey met at least one of three criteria: (1) 
one or more anti-malarials were in stock on the day of 
the survey, (2) one or more anti-malarials were in stock 
in the 3 months preceding the survey, and/or (3) malaria 
blood testing (microscopy or RDT) was available.
Measures
The outlet survey was conducted using a paper question-
naire. Prior to implementing the study, the question-
naire was translated into three languages: Ibo, Hausa and 
Yoruba. The questionnaire was then back-translated into 
English to check the quality of the translation, and any 
inconsistencies were corrected.
Outlets meeting eligibility criteria noted above were 
invited to participate in the survey. Following informed 
consent procedures, an audit of all available anti-malarial 
treatments and RDTs was conducted. Anti-malarial audit 
information included formulation, package size, brand 
name, active ingredients and strengths, manufacturer, 
country of manufacture, reported sale/distribution in 
the week preceding the survey, retail price, and whole-
sale price. Up to three visits were made to all outlets to 
complete the screening process, audit, and provider 
interview, as needed (e.g. where outlets were closed or 
providers were not available).
Training and data collection
A 5-day classroom-based interviewer training was imple-
mented, and was followed by a 2-day field exercise to give 
newly trained interviewers practice with the study meth-
odology and questionnaire. Extra participants for the 
training were recruited to ensure a sufficient number of 
interviewers, and to allow for a selection of best perform-
ing candidates as well as to accommodate any drop outs. 
Tests administered throughout the duration of the training 
were used to identify top performing interviewers. These 
candidates were then selected for a further 3 days of super-
visor and quality controller training. During the inter-
viewer training period, candidates who performed poorly 
after the training were either given additional reinforce-
ment training or dropped from the data collection team.
When the data collection team arrived at the selected 
cluster, data collection team supervisors met with offi-
cials to crosscheck their list of public and any registered 
private sector outlets with that of the government list. 
Data collection teams verified locality boundaries with 
local leaders. The aforementioned census procedures 
were implemented to identify outlets. Data collectors 
interviewed the provider at the outlet after obtaining an 
informed consent. At the end of each day, questionnaires 
were reviewed by supervisors and quality controllers to 
identify any discrepancies or challenges with the quality 
of completed questionnaires. Spot checks were also con-
ducted by quality controllers on 10–20% of the screened 
outlets. Outlets were randomly selected for spot checks 
by the supervisor, who then provided the outlet locations 
to the quality controllers. All physical questionnaires 
were ordered by cluster and serialized. These were then 
sent to Abuja for double data entry.
Data preparation and analysis
A Microsoft Access (Microsoft Corporation, Redmond, 
Washington, USA) database with built-in range checks 
was used to conduct double data entry of physical ques-
tionnaires. Daily supervisor and data collector monitor-
ing sheets were collated in a Microsoft Excel (Microsoft 
Corporation, Redmond, Washington, USA) spreadsheet, 
which along with the physical questionnaires, were used 
to cross-check entered data.
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Standard ACTwatch indicators were calculated in line 
with previous outlet surveys [12, 14, 15]. Anti-malarials 
were classified as ACT, non-artemisinin therapy, and oral 
or non-oral artemisinin monotherapy. ACT were fur-
ther classified as QAACT or non-quality assured ACT 
QAACT by matching product information to lists of 
WHO prequalified anti-malarials and Global Fund anti-
malarial procurement lists.
Availability of oral AMT was calculated using the 
total number of outlets stocking any anti-malarial as the 
denominator. Market share was defined as the relative 
distribution of anti-malarials to individual consumers 
in the week preceding the survey. In order to allow for 
meaningful market share comparisons between products, 
information about anti-malarial distribution was stand-
ardized to the adult equivalent treatment dose (AETD). 
AETD is the amount of active ingredient necessary to 
treat a 60 kg adult according to WHO treatment guide-
lines [17]. Volumes distributed were calculated by con-
verting provider reports on the number of anti-malarials 
sold in the week prior to the survey into AETDs. Volumes 
were therefore the number of AETDs sold or distributed 
by a provider in the 7 days prior to the survey. All dosage 
forms were considered when measuring volumes to pro-
vide a complete assessment of anti-malarial market share. 
Market share was also calculated on a sub-set of the data 
to illustrate the distribution of oral AMT products by 
manufacturer.
Anti-malarial price was collected in Nigerian Naira and 
converted to United States (US) dollars based on official 
exchange rates for the data collection period. The inter-
quartile range (IQR) was calculated to demonstrate price 
dispersion. Price was calculated in two different ways. 
First, median private sector price per AETD was calcu-
lated for oral AMT, QAACT, chloroquine, and sulfadox-
ine–pyrimethamine (SP). AETD price measures included 
only tablet formulations given differences in unit costs for 
tablet and non-tablet formulations, which exist for anti-
malarials other than QAACT. Second, the median price 
of oral AMT and QAACT was also presented as the price 
of pre-packaged therapy of oral AMT (typically 12 tablets 
of 50  mg; in comparison 1 AETD for artesunate 50  mg 
tablets is about 20 tablets), pre-packaged oral AMT for a 
child (i.e. 160 mg/80 ml, suspension), pre-packaged ther-
apy for a 60 kg adult (i.e. AL 20/120, package size of 24 
tablets), and pre-packaged therapy for a 10 kg child (i.e. 
AL 20/120 package size of 6 tablets).
All data cleaning and analysis was completed using 
Stata 13.1 (©StataCorp, College Station, TX). All point 
estimates were weighted using survey settings and all 
standard errors calculated taking account of the clustered 
and stratified sampling strategy with the relevant suite of 
survey commands in STATA.
Results
Sample
A total of 13,480 outlets were screened for availability 
of anti-malarials and/or malaria blood testing services. 
Of screened outlets, 3624 were stocking anti-malarials 
or testing on the day of the survey or within the past 
3  months, and all of these outlets were subsequently 
interviewed. A total of 33,539 anti-malarials were 
audited, of which 1742 were oral AMT products (5% of 
all anti-malarial products audited).
Availability
Table 1 shows the availability of oral AMT among anti-
malarial stocking outlets in the public and private sector. 
Availability of oral AMT was higher in the private sector 
than the public sector (37.3% versus 2.0%, respectively) 
and was most commonly available among pharmacies 
(84.0%) followed by PPMVs (38.7%). Oral AMT was 
commonly available in the private sector in both urban 
(39.0%) and rural areas (36.4%) (Table 1).
Product information
Table  2 summarizes product information for audited 
oral AMT products. Of the 1740 oral AMT products 
audited with complete product information, almost all 
were artesunate products (n = 1731), with the exception 
Table 1 Availability of oral AMT, among outlets stocking at least one antimalarial, by outlet type
Public health 
facility
Total public 
sector
Private for-profit 
facility
Pharmacy PPMV (drug 
store)
General retailer Total private 
sector
%
(95% CI)
%
(95% CI)
%
(95% CI)
%
(95% CI)
%
(95% CI)
%
(95% CI)
%
(95% CI)
National N = 108 N = 204 N = 221 N = 225 N = 2701 N = 96 N = 3266
1.8 (0.7, 4.6) 2.0 (0.9, 4.7) 17.1 (5.9, 40.3) 84.0 (73.1, 91.1) 38.7 (27.5, 51.2) 18.7 (6.4, 43.6) 37.3 (27.1, 48.8)
Urban areas N = 98 N = 106 N = 177 N = 209 N = 2153 N = 78 N = 2632
10.1 (2.7, 31.5) 9.8 (2.9, 28.4) 15.6 (8.2, 27.7) 87.1 (78.2, 92.7) 37.2 (30.1, 44.9) 31.0 (15.1, 53.3) 39.0 (32.2, 46.3)
Rural areas N = 90 N = 98 N = 44 N = 16 N = 548 N = 18 N = 634
0.8 (0.3, 2.6) 1.1 (0.4, 2.9) 17.6 (4.6, 48.5) 69.2 (34.9, 90.4) 39.5 (23.6, 58.0) 14.9 (2.6, 52.8) 36.4 (21.6, 54.3)
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of a few dihydroartemisinin products. The most com-
monly audited oral AMT product was from Vietnam, 
branded as  Artesunat®, manufactured by Mekophar 
Chemical Pharmaceutical Joint Stock Company and for-
mulated as tablets (n =  675) or suspensions (n =  470). 
Most of the other oral AMT products were from China, 
and produced by four different manufacturers, with 
most manufacturing two or more different brands. Both 
MD  Artesunate® (n =  213) and  Actitesunate® (n =  18) 
were manufactured by Jiangsu Ruinian Qianjin Phar-
maceuticals;  Gricin® (n = 103) and Cusnat  Artesunate® 
(n =  33) were manufactured by Greenfield Pharmaceu-
tical (Jiangsu) Co. Limited; Lever  Artesunate® (n = 82), 
 Adamsnate® (n = 31) and  Codisin® (n = 9) were manu-
factured by Adams Pharmaceutical Co. Ltd. Oral AMT 
was also imported from India, with the most commonly 
audited product,  Aretmed® (n  =  99) manufactured by 
Medrel Pharmaceuticals (India) Private Ltd. (Table 3).
Artesunate tablet products had a strength of 50 mg (12 
tablets/blister) or 100  mg (6 tablets/blister). Oral AMT 
suspensions contained 160 mg/80 ml. Available photos of 
the products can be found in Additional file 2.
Market share
Figure  1 shows the national level anti-malarial market 
share for each type of anti-malarial distributed: ACT, 
non-artemisinin therapies, non-oral and oral AMT. 
About half of all anti-malarials distributed in Nigeria 
were ACT, including QAACT (39.0%) and non-QA ACT 
(11.2%). Other commonly distributed anti-malarials were 
non-artemisinins including SP (29.0%) and chloroquine 
(16.2%). Oral AMT accounted for 2.5% of the anti-malar-
ial market nationally in 2015 (Fig. 1).
Figure  2 illustrates the market share of oral AMT by 
country of manufacturer and manufacturer. Of all oral 
AMT distributed, 52.3% of the market share was for a sin-
gle brand manufactured in Vietnam by Mekophar. One in 
three oral AMT products distributed (35.1%) were manu-
factured in China by Jiangsu Ruinian Qianjin Pharmaceu-
tical (12.3%), Greenfield Pharmaceutical (Jiangsu) (12.3%) 
or Adams Pharmaceutical (Anhui) (7.2%). In addition, 
12.5% of the oral AMT products distributed were from 
India, manufactured by Medrel Pharmaceutical (Fig. 2).
Table 2 Product catalogue of oral AMT products audited in Nigeria, 2015
Country of manufacture Manufacturer Brand Package size Strength (mg) N
Artesunate tablet
 China Adams Pharmaceutical (Anhui) Company Ltd. Adamsnate 12 50 31
Lever artesunate 12 50 82
Greenfield Pharmaceutical (Jiangsu) Company Ltd. Cusnat artesunate 12 50 33
Gricin 12 50 103
Jiangsu Ruinian Qianjin Pharmaceutical Actitesunate 12 50 18
MD artesunate 6 100 213
Jiangxi Xierkangtai Pharmaceutical Company Askasunate 12 50 6
 India Halex Pharmaceutical Pvt. Vatunate 6 100 1
Medrel Pharmaceutical (India) Pvt. Ltd. Aretmed 12 50 99
 Vietnam Mekophar Chemical Pharmaceutical Joint Stock Company Artesunat 12 50 675
Artesunate suspension
Mekophar Chemical Pharmaceutical Joint Stock Company Artesunat 80 ml 160/80 ml 470
Dihydroartemisinin tablet
 China Adams Pharmaceutical (Anhui) Company Ltd. Codisin 8 60 3
Dihydroartemisinin suspension
 China Adams Pharmaceutical (Anhui) Company Ltd. Codisin 80 ml 160/80 ml 6
Total oral AMT 1740
Table 3 Median private sector price for anti-malarials
a Adult equivalent treatment dose
N USD IQR
Price per  AETDa
 Oral AMT 1228 $2.84 $2.44–$3.25
 QAACT 8765 $1.69 $1.27–$2.44
 SP 5745 $0.51 $0.46–$0.51
 Chloroquine 1020 $0.25 $0.12–$0.49
Price per package
 Artesunate tablets 1226 $1.78 $1.52–$2.03
 Artesunate suspensions 458 $2.54 $2.28–$3.04
 QA AL-adult pack 1747 $1.52 $1.01–$1.78
 QA AL-child package 1557 $0.76 $0.51–$1.01
 AL suspension 1990 $3.04 $2.44–$3.55
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Figure 3 illustrates the oral AMT market share for each 
outlet type. Most oral AMT was distributed by PPMVs 
accounting for 82.2% of oral AMT distributed, followed 
by pharmacies (11.8%) and private for-profit facilities 
(4.4%). Oral AMT was rarely distributed by the public 
sector (Fig. 3).
Price
The median price of an AETD of oral AMT was $2.84 
and up to 11 times more expensive than other anti-
malarials: QAACT ($1.69), SP ($0.51) or chloroquine 
($0.25) (Table 3).
The median price of pre-packaged artesunate tablets 
($1.78) was only slightly more expensive than the price 
of pre-packaged QA AL for an adult ($1.52). The median 
price of pre-packaged artesunate suspension for a child 
($2.54) was three times more expensive than the price of 
pre-package of QA AL for a child ($0.76) (Table 3).
Discussion
Oral AMT is commonly available in Nigeria’s anti-malar-
ial market, despite the country’s ban on this anti-malarial 
and calls from WHO to halt the importation and distri-
bution of oral AMT. Findings on availability, distribution, 
and product information can inform the urgent action 
needed to remove products from the market.
Oral AMT availability in the private sector
Oral AMT was commonly available in the private sec-
tor with over one in three outlets stocking at least one 
product on the day of the survey. The vast majority of 
pharmacies, and nearly 40% of PPMVs were stocking oral 
AMT. Strategies to rapidly remove oral AMT from the 
private sector should target these outlet types. Remov-
ing products from pharmacies may be less labor inten-
sive than removal from PPMVs given that pharmacies 
are much fewer in number. PPMVs are ubiquitous, and 
furthermore, they were responsible for 76% of the total 
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anti-malarial market share in 2015 [18], and distribute 
most of the oral AMT as evidenced in this study, making 
removal of oral AMT from their shelves critical.
Previous ACTwatch outlet surveys suggest that avail-
ability of oral AMT in Nigeria was in decline prior to 
2015. In 2009, nearly half of all anti-malarial-stocking 
private sector outlets had oral AMT in stock (46%), and 
availability declined to 35% in 2011 and 25% in 2013 [4]. 
A continued decline in availability would be expected 
given the ban on oral AMT in place for several years 
prior to the 2015 survey [19]. However, it appears that 
oral AMT products continue to receive legal registra-
tion status granted by NAFDAC. NAFDAC registration 
numbers were found on the packages of common oral 
AMT products. While the National Malaria Elimination 
Programme (NMEP) within the Ministry of Health has 
banned oral AMT, halting product registration under 
NAFDAC has not yet been achieved. There is need to 
engage NAFDAC towards halting registration for these 
banned products. Several challenges have been docu-
mented with the registration process of medicines in 
Nigeria, including a lack of publically available lists of 
registered medicines, a lack of guidelines on the selec-
tion and retention of NAFDAC committee members, 
and an absence of conflict of interest forms for NAFDAC 
members [20]. It has been suggested that oral AMT 
is gradually being phased out by not registering any 
new oral AMT products and not renewing those with 
licenses that are due to expire [21]. Progress must be 
closely monitored to ensure that there is no new licens-
ing of oral AMT products.
Oral AMT distribution
Oral AMT accounted for a small percentage of all anti-
malarial distribution; only 2.5% of all anti-malarials 
distributed were oral AMT products. This is an improve-
ment over previous years when oral AMT market share 
was higher (2009, 8.1%; 2011, 4.1%). However, as of 
2015, oral AMT market share had not improved over 
2013 levels (2.0%). Continued oral AMT distribution 
must be addressed. Oral AMT is not the only set of 
anti-malarial medicines that is not indicated for malaria 
case management but continues to be widely avail-
able and distributed. It has been over a decade since 
the use of non-artemisinins including chloroquine and 
SP were phased out in favor of ACT for first-line treat-
ment. Yet both chloroquine and SP retain a substantial 
market share, accounting together for nearly half of all 
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anti-malarial distribution (45%). While SP is indicated for 
preventative therapy during pregnancy, its continued use 
for case management in Nigeria is evident in the high rel-
ative market share and product packaging promoting use 
to treat infection in people of all ages [3]. Furthermore, 
the use of these non-artemisinins, particularly chloro-
quine given concerns around efficacy, may pose greater 
threats to patient health and safety at least in the short 
term as compared to the longer term threats to drug effi-
cacy posed by use of oral AMT. Strategies to remove oral 
AMT may be applied more broadly to ensure that other 
non-recommended anti-malarial medicines are removed 
from the market.
Chloroquine, SP and QAACT all had much higher 
relative market share as compared with oral AMT. This 
may be driven in part by price. Comparing the price of an 
adult equivalent treatment dose, oral AMT was 11 times 
more expensive than the least expensive treatment, chlo-
roquine. A package of artesunate tablets was about $0.25 
more expensive than an adult package of QA AL (first-
line ACT treatment), thus the cost of oral AMT may in 
part explain lower levels of distribution. That said, it may 
also be the case that artesunate tablets are acquired and/
or consumed in amounts much lower than a full course 
of treatment. This would make the overall cost of treat-
ment with artesunate tablets perhaps comparable or 
cheaper than the cost of treatment with an ACT or popu-
lar non-artemisinin. The practice of dispensing and con-
suming artesunate tablets in amounts much lower than a 
full course has been documented in Myanmar, where oral 
AMT remains commonly available in the private sector 
[14, 15]. If this is indeed a common practice in Nigeria, 
the threats to patient health and safety and to the efficacy 
of artemisinin is high. Finally, if a consumer or patient 
was seeking treatment for a child, the results of the study 
also illustrate that artesunate formulated as a suspen-
sion was less expensive than a suspension of AL. In this 
instance, there may be a financial incentive for a con-
sumer to choose the less expensive suspension, artesu-
nate, over the first-line treatment for their child.
Finally, oral AMT products appeared to be marketed as 
powerful treatment that can cure drug-resistant malaria 
and severe malaria (see Additional file 3). It may be that 
these products are not competing directly with ACT and 
non-artemisinins for management of all types of malaria 
infection, but instead are directed towards those infec-
tions that are perceived to be drug resistant or severe.
A diverse oral AMT product market
In contrast to other research which has shown that the 
distribution of oral AMT within a country is dominated 
by the presence of a single manufacturer and product 
on the market [7], this study found a diverse oral AMT 
market in Nigeria. Oral AMT products on the market in 
2015 included 11 unique brands from six manufacturers 
and were imported from Vietnam, China and India. The 
Mekophar artesunate products from Vietnam dominated 
the market with about half of the oral AMT market share. 
However, four other manufacturers from China and India 
each held substantial proportions of market share. This 
finding suggests that the persistence of oral AMT prod-
ucts on the shelves in Nigeria is not the result of a single 
drug license or importation from one country. There may 
be a variety of existing agreements in place with manu-
facturers, importers and private buyers facilitating the 
presence of such a diverse set of products. Removing oral 
AMT products from the shelves will require addressing 
importation of multiple products from multiple manu-
facturers and three countries. Encouragingly, there are 
recent reports that a national task force has been estab-
lished between the NMEP and NAFDAC to enforce the 
ban on oral AMTs [22]. However, to the authors’ knowl-
edge, there is no further documentation publicly avail-
able that reports the remit of the task force or strategies 
that will be employed to enforce this ban.
Strategies to remove oral AMT must be prioritized 
and should be of imminent concern given the threats 
to malaria control and elimination posed by oral AMT 
consumption. Other countries that have successfully 
removed oral AMT from the market place have used a 
multi-faceted approach. For example, in Cambodia the 
National Malaria Control Programme took measures to 
improve enforcement of the oral AMT ban including pri-
vate sector outlet inspections and confiscation of prod-
ucts performed by a new cadre of officials dedicated to 
enforcement of the ban [23]. This was complemented 
with a variety of activities to raise awareness of the ban 
targeting both providers and consumers, such as the use 
of posters to communicate about specific banned prod-
ucts and the dangers of using these products. Strategies 
in Cambodia were successful in removing oral AMT 
from the market [24]. The success may in part have been 
attributable to a concurrent private sector ACT subsidy 
program improving access to affordable first-line ACT 
treatment in the private sector [25]. Indeed, it may have 
been the private sector ACT subsidy programme imple-
mented in Nigeria from 2010 to 2016 that led to initial 
reductions in market share for oral AMT [16]. Future 
strategies to remove oral AMT from the market in Nige-
ria must start with product registration as evidence 
suggests that oral AMT products are still granted legal 
registration by NAFDAC.
Recommendations
Oral AMT products in Nigeria were labelled as originat-
ing from Vietnam, China and India. This is contrary to 
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the World Health Assembly Resolution 60.18 from 2007 
[26] and the authors call on these countries to comply 
with this in the interests of global public health. The last 
available WHO update on ‘Marketing of oral artemisinin-
based monotherapy medicines—positions expressed by 
manufacturers’ is from December 2015 [27]. Only two 
of the seven manufacturers listed in Table  2 are named 
in this document. The authors call on the Global Malaria 
Programme to update this and for the new Director-
General to lead discussions on how to end this practice—
that is especially dangerous for malaria endemic Africa. 
If needed this issue should be brought before the World 
Health Assembly in 2018 to give countries continuing 
to manufacture oral AMT the opportunity to explain 
their manufacturing policy in relation to global malaria 
control.
At a national level, additional enforcement strategies 
should be implemented to ensure full removal or oral 
AMT from the market. For these to be most effective, 
there is need for coordination between the National 
Malaria Elimination Programme and NAFDAC to 
ensure that banned products are no longer legally reg-
istered. In addition, it is recommended that efforts focus 
on the removal of registered and unregistered products 
from the private sector, particularly by targeting PPMVs 
where oral AMT is most commonly available and 
distributed.
Finally, the results from the study in Nigeria show the 
need for further information about supply practices and 
supply chains for oral AMT products, as well as infor-
mation about provider and consumer preferences and 
practices. In particular, understanding consumer and 
provider choice and perceptions around the efficacy of 
different types of anti-malarials may help to explain why 
oral AMT continues to be distributed and administered 
by providers.
Limitations
The outlet survey includes an audit of all anti-malarials 
by asking the provider to show the interviewer all treat-
ments that are in stock. Given that oral AMT has been 
banned in Nigeria, providers may have been reluctant 
to show oral AMT products to interviewers. Data from 
this study may, therefore, produce underestimates for the 
extent to which oral AMT is available and is contribut-
ing to market share. The outlet survey is a tool to provide 
estimates of availability, price and market share. While 
beyond the scope of this study, qualitative information 
on provider awareness of the ban and consumer prefer-
ences would have added valuable contextual information 
to assist with the interpretation of findings.
Conclusion
Nigeria has one of the highest burdens of malaria in the 
world, accounting for an estimated 23% of cases globally 
and one-third of all deaths. As such, the availability and 
distribution of oral AMT is of grave concern and poses 
a serious threat to malaria control in Nigeria and the rest 
of the world. The evidence from this study illustrates that 
oral AMT is available and distributed by the private sec-
tor, namely though PPMVs, and comprises of 11 differ-
ent products manufactured by three countries—India, 
Vietnam and China. Strategies to remove oral AMT from 
the market in Nigeria must start with product registra-
tion as evidence suggests that oral AMT products are 
still granted legal registration by NAFDAC. Strategies are 
required to remove registered and unregistered products 
from the private sector, particularly by targeting PPMVs 
where oral AMT is most commonly available and distrib-
uted. Finally, there is urgent need for action in Vietnam, 
China and India where oral AMT is still manufactured 
and exported.
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